Axe Compute Inc.

Listed Company

AGPUCIK 0001446159NasdaqNon-AcceleratedSmaller ReportingFinance ServicesDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-233.10M

Total Assets

$52.89M

Equity

$47.72M

Shares Out

5.54M

Op. Cash Flow

$-9.88M

Business

Axe Compute Inc. applies artificial intelligence to oncology drug discovery and development, using a proprietary biobank of over 150,000 tumor samples and machine learning to generate tumor drug-response predictions. It offers AI-driven drug discovery services (PEDAL), tumor-specific 3D in vitro models, CLIA-certified clinical tumor profiling and biomarker testing, and formerly produced the FDA-cleared STREAMWAY® automated medical fluid disposal system. The company operates two reportable segments — a Pittsburgh life‑science services segment and an Eagan medical device segment — and serves biopharmaceutical partners and medical facilities through direct collaborations and product distribution channels.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	125,284	84,812	2	2	1
Gains (losses) on digital assets	−152	0	—	—	—
Cost of revenues	72,622	78,285	—	—	—
General and administrative	26	7	8	11	11
Operations, research and development	2	2	3	4	3
Sales and marketing	406,247	833,199	1	1	774,530
Total operating expenses	29	10	—	—	—
Total operating (loss)	−181	−10	−12	−26	−20
Other income	806,037	89,367	152,685	185,646	184,528
Other expense	−8,969	−11,468	−64,967	−5,275	−239,631
Gain (loss) on derivative instruments	−53	1,376	12,457	115,647	164,902
Loss from continuing operations	−233	−10	−12	—	—
Loss from discontinued operations	−241,556	−2	−2	—	—
Net loss	−233	−13	−14	−26	−20
Loss from continuing operations (in dollars per share)	−13.36	−28.12	−2.99	—	—
Loss from discontinued operations (in dollars per share)	−0.01	−6.71	−0.49	—	—
Net loss per common share, basic and diluted (in dollars per share)	−13.37	−34.83	−3.48	−6.98	−0.36
Weighted average shares used in computation basic and diluted (in shares)	17	363,583	4	4	55

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2024 2024-09-30	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash and cash equivalents	11	611,822	—	9	22
Accounts receivable, net	32,120	34,154	—	277,641	331,196
Prepaid expense and other assets	280,904	318,539	—	512,078	526,801
Crypto assets at fair value	24	0	—	—	—
Digital asset receivable	7	0	—	—	—
Current assets of discontinued operations	0	1	—	79,249	—
Total current assets	43	2	—	10	23
Locked crypto receivable at fair value, net of current portion	8	0	—	—	—
Property and equipment, net	223,128	347,588	—	491,214	2
Lease right-of-use assets	1	2	—	3	211,893
Other long-term assets	148,887	149,433	—	105,509	75,618
Non-current assets of discontinued operations	0	202,337	—	902,665	—
Total assets	53	5	—	14	26
Accounts payable	2	1	—	1	943,452
Note payable	107,951	0	—	150,408	0
Accrued expenses and other liabilities	2	1	—	2	2
Contract liabilities	144,076	224,076	—	302,499	602,073
Lease liability	653,743	555,169	—	444,897	94,237
Current liabilities of discontinued operations	0	533,384	—	174,839	—
Total current liabilities	4	4	—	4	4
Lease liability net of current portion	904,495	2	—	2	86,082
Non-current liabilities of discontinued operations	0	23,487	—	58,002	—
Total liabilities	5	5	—	6	4
Common stock, $.01 par value, 200,000,000 shares authorized, 4,083,173 and 444,475 shares outstanding as of December 31, 2025, and December 31, 2024, respectively	40,832	4,445	—	40,629	39,382
Additional paid-in capital	461	180	—	176	176
Accumulated deficit	−414	−180	—	−168	−154
Total stockholders equity (deficit)	48	−202,610	2	8	22
Total liabilities and stockholders equity (deficit)	53	5	—	14	26

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	129,038	132,337	244,788	1	1
Amortization of operating lease right-of-use assets	559,538	495,869	480,020	—	—
Write off of aged accounts payable and accrued expenses	−676,678	0	—	—	—
Vesting expense	1	906	1,167	166,312	715,938
Shares of common stock issued to employees and nonemployees	16	99,253	—	—	—
(Gain) loss on derivative instruments	53	−1,376	−12,457	—	—
Loss on disposal of property and equipment	0	803	903	—	—
Loss on disposal of intangible assets	0	4,738	0	—	—
Accounts receivable	2,034	45,795	19,003	−23,000	−20,769
Prepaid expense and other assets	33,603	119,687	−41,146	78,425	−194,363
Accounts payable	1	−169,105	399,207	−78,322	−350,296
Accrued expenses and other	751,132	−154,521	−384,149	869,987	−499,563
Contract liabilities	−80,000	−45,755	−266,803	41,819	54,548
Operating lease liability	−555,170	−407,060	−446,483	—	—
Net cash used in continuing operating activities:	−10	−10	−12	—	—
Crypto assets purchased	−33	0	—	—	—
Purchase of property and equipment	0	−9,510	−21,533	−419,869	−910,429
Net cash used in continuing investing activities:	−33	−9,510	−47,550	—	—
Proceeds from issuance of common stock and warrants	56	5	0	7	51
Costs to issue common stock and warrants	−4	−870,960	0	—	—
Proceeds from issuance of financing note payable	264,048	275,098	364,721	0	—
Repayment of note payable	−156,097	−425,506	−214,313	0	—
Payments for taxes related to net share settlement of restricted stock units	−58,369	0	—	—	—
Net cash provided by continuing financing activities	52	4	148,899	—	—
Net cash used in operating activities	−82,538	−2	−1	—	—
Net cash provided by investing activities	625,000	32,000	−254,821	—	—
Net cash provided by (used in) financing activities	0	0	0	—	—
Net cash provided by (used in) discontinued operations	542,462	−2	−2	—	—
Net increase (decrease) in cash	10	−8	−13	−6	28
Cash payments for interest	8,960	11,466	13,904	3,821	690,508
Digital assets received pursuant to securities purchase agreements	63	0	—	—	—
Digital asset receivable received pursuant to securities purchase agreements	97	0	—	—	—
Vested ATH claimed from Locked ATH Receivable at Fair Value	3	0	—	—	—
Shares issued for vested restricted stock units, net of shares withheld for taxes	502	0	—	—	—
Equipment transferred from discontinued operations	0	5,140	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro